Ai-driven multi-modality platform for neurodegenerative disease profiling and drug screening
NeuroKaire offers an AI-based platform integrating computer vision, omics, and clinical data to profile neurodegenerative diseases and screen drugs. The platform has been clinically validated and supports drug development and patient treatment decisions.
Overview
NeuroKaire's innovative platform leverages AI, computer vision, and omics to create a comprehensive profile of neurodegenerative diseases using patient-derived neuronal cells. This platform enables the integration of clinical data to provide unique insights into disease mechanisms, subtypes, and drug effects. By automating the quantification of neuroplasticity and capturing molecular and inflammatory effects, our platform supports drug screening and insights into disease progression prior to human trials.
Technical specifications
Key features:
- AI-driven integration of computer vision and omics for comprehensive disease profiling
- Automated quantification of neuroplasticity and neuroinflammation in patient-derived neurons
- Clinical data integration for detailed characterization of disease and patient subtypes
- Supports drug candidate prioritization and treatment decision processes
The platform utilizes a large patient biobank and has been validated in clinical settings, proving its utility in advancing drug development and providing real-world evidence for treatment decisions.
Technology readiness level
Our platform has achieved a Technology Readiness Level of 9, indicating it is fully operational and routinely used in clinical environments for supporting drug development and treatment decisions.
About NeuroKaire
NeuroKaire, formerly known as GenetikaPlus, is a precision psychiatry company that utilizes stem cell technology and artificial intelligence to personalize depression treatment. The company’s core technology, BrightKaire, involves a blood test where patient samples are reprogrammed into neuronal cells. These derived neurons are then exposed to various antidepressant medications in a laboratory setting to measure biological responses and predict the most effective treatment for the individual. By integrating these biological insights with genetic testing, the company aims to move beyond traditional trial-and-error prescribing methods.
This technology is designed to help clinicians reduce the time required to find effective antidepressant therapy, potentially minimizing unnecessary suffering, adverse side effects, and healthcare costs for patients with major depressive disorder. By providing biologically informed, data-driven reports, NeuroKaire aims to support more accurate, personalized treatment plans. Beyond its clinical diagnostic offerings, the company also works with pharmaceutical and biotechnology partners to leverage its platform for drug development, aiming to advance precision medicine across broader psychiatric and neurological conditions.
Inquire about this partnering listing
Industry applications
delivered to your inbox.